SK bioscience Co.,Ltd. (KRX:302440)

SK bioscience Statistics

Total Valuation

SK bioscience has a market cap or net worth of KRW 3.24 trillion. The enterprise value is 3.14 trillion.

Market Cap	3.24T
Enterprise Value	3.14T

Important Dates

The next estimated earnings date is Wednesday, August 12, 2026.

Earnings Date	Aug 12, 2026
Ex-Dividend Date	n/a

Share Statistics

SK bioscience has 78.46 million shares outstanding. The number of shares has increased by 0.80% in one year.

Current Share Class	78.46M
Shares Outstanding	78.46M
Shares Change (YoY)	+0.80%
Shares Change (QoQ)	+0.05%
Owned by Insiders (%)	0.17%
Owned by Institutions (%)	2.44%
Float	25.96M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.87
PB Ratio	1.60
P/TBV Ratio	1.97
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-37.71
EV / Sales	4.72
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-17.46

Financial Position

The company has a current ratio of 4.04, with a Debt / Equity ratio of 0.27.

Current Ratio	4.04
Quick Ratio	3.36
Debt / Equity	0.27
Debt / EBITDA	n/a
Debt / FCF	-2.99
Interest Coverage	-14.28

Financial Efficiency

Return on equity (ROE) is -4.34% and return on invested capital (ROIC) is -9.35%.

Return on Equity (ROE)	-4.34%
Return on Assets (ROA)	-3.24%
Return on Invested Capital (ROIC)	-9.35%
Return on Capital Employed (ROCE)	-5.70%
Weighted Average Cost of Capital (WACC)	8.25%
Revenue Per Employee	725.65M
Profits Per Employee	-90.82M
Employee Count	917
Asset Turnover	0.23
Inventory Turnover	2.97

Taxes

Income Tax	-31.64B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -8.43% in the last 52 weeks. The beta is 0.93, so SK bioscience's price volatility has been similar to the market average.

Beta (5Y)	0.93
52-Week Price Change	-8.43%
50-Day Moving Average	42,326.00
200-Day Moving Average	47,666.50
Relative Strength Index (RSI)	47.96
Average Volume (20 Days)	183,171

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, SK bioscience had revenue of KRW 665.42 billion and -83.29 billion in losses. Loss per share was -1,063.58.

Revenue	665.42B
Gross Profit	63.79B
Operating Income	-152.91B
Pretax Income	-119.90B
Net Income	-83.29B
EBITDA	-57.64B
EBIT	-152.91B
Loss Per Share	-1,063.58

Balance Sheet

The company has 890.16 billion in cash and 538.00 billion in debt, with a net cash position of 352.16 billion or 4,488.56 per share.

Cash & Cash Equivalents	890.16B
Total Debt	538.00B
Net Cash	352.16B
Net Cash Per Share	4,488.56
Equity (Book Value)	2.02T
Book Value Per Share	22,581.94
Working Capital	943.61B

Cash Flow

In the last 12 months, operating cash flow was -2.77 billion and capital expenditures -177.08 billion, giving a free cash flow of -179.85 billion.

Operating Cash Flow	-2.77B
Capital Expenditures	-177.08B
Depreciation & Amortization	95.27B
Net Borrowing	100.50B
Free Cash Flow	-179.85B
FCF Per Share	-2,292.30

Margins

Gross margin is 9.59%, with operating and profit margins of -22.98% and -12.52%.

Gross Margin	9.59%
Operating Margin	-22.98%
Pretax Margin	-18.02%
Profit Margin	-12.52%
EBITDA Margin	-8.66%
EBIT Margin	-22.98%
FCF Margin	n/a

Dividends & Yields

SK bioscience does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.80%
Shareholder Yield	-0.80%
Earnings Yield	-2.57%
FCF Yield	-5.55%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

SK bioscience has an Altman Z-Score of 2.92 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.92
Piotroski F-Score	2